1. Cell-mediated Immunity in Human Acute Leukemia
- Author
-
Levine Ph, McCoy Jl, J. C. W. Chau, H. C. Ho, R. Oldham, Leventhal Bg, Ronald B. Herberman, and Devron H. Char
- Subjects
Chemotherapy ,Acute leukemia ,business.industry ,medicine.medical_treatment ,Immunotherapy ,medicine.disease ,Lymphoma ,Leukemia ,Nasopharyngeal carcinoma ,Antigen ,Delayed hypersensitivity ,hemic and lymphatic diseases ,Immunology ,medicine ,business - Abstract
The general cell-mediated immunological reactivity of patients with acute leukemia has been found to be intact, although it may be depressed by extensive disease or by chemotherapy. Patients with acute leukemia also have cellular immune reactivity against tumor associated antigens, as measured by skin tests for delayed hypersensitivity, lymphocyte stimulation, and 51Cr release cytotoxicity. Skin reactions to autologous and allogeneic crude membrane extracts of blast cells correlated with disease state, positive in many patients in remission and negative in most patients in relapse. Extracts of human lymphoid tissue culture cell lines derived from lymphomas or leukemia also gave positive reactions in patients with acute leukemia, and also in patients with lymphoma and nasopharyngeal carcinoma. The antigens detected in the skin tests with the lymphoid cell lines appear to be different from those associated with Epstein-Barr virus (EBV) and from those detected in the 51Cr release assay. Evidence is presented which suggests a complex variety of antigens on blast cells and on the cell lines. Although leukemia associated antigens were also detected by lymphocyte stimulation and by cytotoxicity assays, the results did not correlate with the skin tests nor with each other. The possible use of these assays for monitoring the chemotherapy and immunotherapy of acute leukemia patients is discussed.
- Published
- 2015